Margaret M. FitzPatrick
CIK: 0001873879
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (12 total)
- Sep 1, 2026ANTX
AN2 Therapeutics, Inc.
Purchase(P)Direct2.1K shares at avg. $5.53$12K - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
23.7K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
10.4K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
Disposition(D)DirectStock Option (right to buy)
10.4K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
Disposition(D)DirectStock Option (right to buy)
23.7K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
11.5K shares- - Mar 19, 2026ANTX
AN2 Therapeutics, Inc.
Disposition(D)DirectStock Option (right to buy)
11.5K shares- - Feb 20, 2026ANTX
AN2 Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
20.4K shares- - Sep 9, 2025VTGN
Vistagen Therapeutics, Inc.
Award(A)DirectNon-Qualified Stock Option (right to buy)
17.6K shares- - May 28, 2025ANTX
AN2 Therapeutics, Inc.
Purchase(P)Direct8.6K shares at avg. $1.18$10K - May 22, 2025ANTX
AN2 Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
19.1K shares- - Sep 6, 2024VTGN
Vistagen Therapeutics, Inc.
Award(A)DirectStock Option (Right to Buy)
14.1K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 1, 2026 |  ANTX AN2 Therapeutics, Inc. | Purchase(P) | 2,098 | $5.53 | $11,602 | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 23,742 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 10,362 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition(D) Stock Option (right to buy) | 10,362 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition(D) Stock Option (right to buy) | 23,742 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 11,463 | - | - | Direct |
| Mar 19, 2026 | ANTX AN2 Therapeutics, Inc. | Disposition(D) Stock Option (right to buy) | 11,463 | - | - | Direct |
| Feb 20, 2026 | ANTX AN2 Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 20,400 | - | - | Direct |
| Sep 9, 2025 |  VTGN Vistagen Therapeutics, Inc. | Award(A) Non-Qualified Stock Option (right to buy) | 17,600 | - | - | Direct |
| May 28, 2025 | ANTX AN2 Therapeutics, Inc. | Purchase(P) | 8,610 | $1.18 | $10,133 | Direct |
| May 22, 2025 | ANTX AN2 Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 19,111 | - | - | Direct |
| Sep 6, 2024 | VTGN Vistagen Therapeutics, Inc. | Award(A) Stock Option (Right to Buy) | 14,100 | - | - | Direct |
1-12 of 12 transactions
About FitzPatrick Margaret M
FitzPatrick Margaret M (SEC CIK 0001873879) files insider reports with the SEC as Director of AN2 Therapeutics, Inc. (ANTX) and Director of Vistagen Therapeutics, Inc. (VTGN).
Signal8 holds 7 ownership filings by FitzPatrick Margaret M, all Form 4s, filed between Sep 10, 2024 and Sep 2, 2026. Those filings report 12 transactions, from Sep 6, 2024 to Sep 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on FitzPatrick Margaret M's filings is in MENLO PARK, CA.
Recent filings by FitzPatrick Margaret M
- Sep 1, 2026: Open-market purchase of ANTX shares (Form 4, code P).
- Mar 19, 2026: Grants or awards of ANTX derivative securities (2 lines, Form 4, code A).
- Mar 19, 2026: Disposition to issuer transactions of ANTX derivative securities (2 lines, Form 4, code D).
- Mar 19, 2026: Grant or award of ANTX derivative securities (Form 4, code A).
- Mar 19, 2026: Disposition to issuer transaction of ANTX derivative securities (Form 4, code D).
Other insiders filing for AN2 Therapeutics, Inc. (ANTX)
- Marks Gilbert Lynn, Director
- Martin Patricia A., Director
- Aziz Kabeer, Director
- Trenor Cameron C. III, Chief Medical Officer
- Readnour Robin Shane, Director
- Williams Sarah Joanne, Principal Accounting Officer